Ginkgo Bioworks Holdings, Inc. (DNA) has been on a downward spiral lately with significant selling pressure. After declining 28.8% over the past four weeks, the stock looks well positioned for a trend ...

The most recent trading session ended with Ginkgo Bioworks Holdings, Inc. (DNA) standing at $8.09, reflecting a -1.94% shift from the previouse trading day's closing. This change was narrower than the ...

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

Reshma is the kind of leader who can deliver that extraordinary future—it only seems crazy because no one’s done it before. I ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a ...

Ginkgo Bioworks (DNA) announced a new contract with the Advanced Research Projects Agency for Health, or ARPA-H, alongside partners Tritica ...

Kewalramani becme the first female CEO of a large, public U.S. biotechnology company after immigrating from India at age 11 ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Shares of Ginkgo Bioworks Holdings, Inc. (DNA) have gained 2% over the past four weeks to close the last trading session at $6.78, but there could still be a solid upside left in the stock if ...

Ginkgo Bioworks and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON, April 10 ...

Trained in internal medicine and nephrology, Reshma once intended to teach, treat patients, and work in a lab after medical ...